Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Sanofi

Pharmaceutical sales down 5% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi
 
4Q Revenues: €9.3 billion (+2%)

4Q Earnings: €1.7 billion (-7%)

FY Revenues: €37.1 billion (+10%)

FY Earnings: €7.4 billion (+8%)

Comments: Pharmaceutical sales were €7.3 billion in the quarter, down 5% at constant exchange rates (CER). Diabetes sales were €1.9 billion, down 13%, impacted by a decline Lantus sales (-20% to €1.5 billion) mainly reflecting higher discounts. Genzyme sales were €1.0 billion in the quarter, up 28% driven by Aubagio sales, up 70% to €272 million. Generics sales were €467 million, up 5%. Oncology sales were €381 million, down 8% impacted by lower sales of Eloxatin in the U.S (-24% to €58 million). Established Rx Products accounted for €2.7 billion, down 10% impacted by generic competition for Plavix (-14% to €455 million). Vaccines were up 15% to €1.4 billion, driven by influenza and Adult Booster vaccines and Meningitis/Pneumonia Vaccines in the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics